Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Borwel
Borwel (Bortezomib Injection 2.5 mg) is a targeted chemotherapy drug used for the treatment of multiple myeloma and mantle cell lymphoma. As a proteasome inhibitor, it prevents cancer cells from degrading unnecessary proteins, leading to cellular stress and apoptosis. Bortezomib is administered either intravenously (IV) or subcutaneously, making it a critical part of cancer therapy.
Uses of Borwel
First-line treatment for multiple myeloma
Therapy for relapsed or refractory multiple myeloma
Treatment of mantle cell lymphoma
Used in combination with other chemotherapeutic agents
Benefits of Borwel
Targeted action against cancer cells
Slows disease progression in multiple myeloma
Enhances response rates when combined with other therapies
Can be administered via IV or subcutaneous injection
Improves overall survival in patients with blood cancers
Mechanism of Action of Borwel
Bortezomib, the active ingredient in Borwel, inhibits the 26S proteasome, a cellular complex responsible for protein degradation. By blocking this process, Borwel disrupts cellular homeostasis, leading to cancer cell apoptosis. This targeted action makes it highly effective against hematologic malignancies such as multiple myeloma and mantle cell lymphoma, reducing tumor burden and improving patient survival.